

# Tsiporah B Shore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/494309/publications.pdf>

Version: 2024-02-01

128  
papers

2,855  
citations

172457

29  
h-index

189892

50  
g-index

129  
all docs

129  
docs citations

129  
times ranked

3834  
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. <i>Blood</i> , 2002, 100, 1525-1531.	1.4	315
2	BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naïve symptomatic multiple myeloma. <i>Blood</i> , 2008, 111, 1101-1109.	1.4	175
3	Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5044-5051.	1.6	164
4	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146
5	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2014, 124, 1183-1191.	1.4	135
6	Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2013, 54, 799-806.	1.3	111
7	Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 795-798.	2.0	106
8	Final results from a defibrotide treatmentâ€‹IND study for patients with hepatic venoâ€‹occlusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , 2018, 181, 816-827.	2.5	95
9	Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a singleâ€‹centre study with focus on emerging pathogens. <i>Mycoses</i> , 2015, 58, 325-336.	4.0	94
10	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
11	An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 405-414.	2.0	61
12	Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. <i>Journal of Clinical Oncology</i> , 2008, 26, 37-43.	1.6	53
13	Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 192-196.	0.4	53
14	DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 965-970.	2.0	52
15	Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1808-1814.	2.0	49
16	Defibrotide for Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 997-1004.	2.0	47
17	Safety and efficacy of plerixafor dose escalation for the mobilization of CD34 hematopoietic progenitor cells in patients with sickle cell disease: interim results. <i>Haematologica</i> , 2018, 103, 770-777.	3.5	47
18	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 740-754.	5.2	42

#	ARTICLE	IF	CITATIONS
19	A meta-analysis of stages I and II Hodgkin's disease. <i>Cancer</i> , 1990, 65, 1155-1160.	4.1	40
20	Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. <i>Cancer</i> , 2006, 106, 616-622.	4.1	40
21	Effectiveness and Safety of Tocilizumab, an Anti-Interleukin-6 Receptor Monoclonal Antibody, in a Patient With Refractory GI Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, e602-e604.	1.6	38
22	Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. <i>American Journal of Hematology</i> , 2012, 87, 433-435.	4.1	38
23	Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. <i>Journal of Clinical Virology</i> , 2015, 71, 51-58.	3.1	36
24	Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S23.	2.0	34
25	Colonization With Levofloxacin-resistant Extended-spectrum $\beta$ -Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 67, 1720-1728.	5.8	34
26	The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. <i>Leukemia and Lymphoma</i> , 2014, 55, 2858-2865.	1.3	30
27	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. <i>Haematologica</i> , 2016, 101, 634-643.	3.5	30
28	Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 565-73.	0.3	30
29	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 831-837.	2.0	29
30	A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1984-1992.	2.0	25
31	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. <i>Blood Advances</i> , 2019, 3, 1858-1867.	5.2	25
32	Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. <i>Clinical Cancer Research</i> , 2013, 19, 1534-1546.	7.0	22
33	Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. <i>Leukemia and Lymphoma</i> , 2019, 60, 1693-1696.	1.3	22
34	Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1469-1473.	1.3	21
35	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1065-1072.	2.0	20
36	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.	2.0	20

#	ARTICLE	IF	CITATIONS
37	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2027-2038.	2.4	20
38	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 297-303.	0.4	19
39	Safety and tolerability of velifermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. <i>Supportive Care in Cancer</i> , 2008, 16, 477-483.	2.2	18
40	How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. <i>Transfusion</i> , 2015, 55, 1147-1153.	1.6	18
41	Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 456-461.	2.0	18
42	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 997-1004.	2.0	18
43	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 349-354.	329.8	18
44	Clinical and Ultrasonic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 827-834.	2.0	17
45	A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1040-1045.	2.0	17
46	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17
47	Cord blood chimerism and relapse after haplo-cord transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 288-297.	1.3	17
48	Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 1693-1700.	5.8	17
49	A Study of a Reduced-Intensity Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies Using Campath-1H as Part of a Graft-versus-Host Disease Strategy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 868-875.	2.0	15
50	A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. <i>Transfusion</i> , 2015, 55, 2010-2016.	1.6	15
51	The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. <i>Transplantation</i> , 2017, 101, e34-e38.	1.0	14
52	Acute myeloid leukemia in a patient with thrombocytopenia with absent radii: A case report and review of the literature. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 245-247.	0.9	13
53	Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 288-293.	2.0	13
54	Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e60-e64.	2.0	13

#	ARTICLE	IF	CITATIONS
55	Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. <i>Leukemia and Lymphoma</i> , 2007, 48, 342-348.	1.3	12
56	Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic Precursor Cell Enumeration with First-Harvest CD34+ Stem Cell Yield. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1867-1875.	2.0	12
57	Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2016, 57, 2555-2559.	1.3	12
58	Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 789-797.	2.0	11
59	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 930-937.	2.0	10
60	Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 618.e1-618.e10.	1.2	10
61	Avoiding pitfalls in bone marrow engraftment analysis: a case study highlighting the weakness of using buccal cells for determining a patient's constitutional genotype after hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2013, 15, 391-395.	0.7	9
62	Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. <i>Blood</i> , 2014, 124, 501-501.	1.4	9
63	A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma. <i>PLoS ONE</i> , 2010, 5, e8714.	2.5	9
64	C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. <i>Bone Marrow Transplantation</i> , 2022, 57, 1445-1447.	2.4	9
65	Haplo-cord transplant: HLA-matching determines graft dominance. <i>Leukemia and Lymphoma</i> , 2017, 58, 1512-1514.	1.3	7
66	Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone,) Tj ETQqO 0 0 rgBT 1,4 Overlock 7,10 Tf 50 30 2751-2751.	1.4	7
67	Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. <i>Leukemia and Lymphoma</i> , 2013, 54, 885-888.	1.3	6
68	CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a "test dose" Strategy to Target Busulfan Exposure. <i>Blood</i> , 2014, 124, 543-543.	1.4	6
69	Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S132.	2.0	5
70	Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. <i>Blood Advances</i> , 2020, 4, 5146-5156.	5.2	5
71	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 466-473.	2.0	4
72	Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. <i>Blood</i> , 2014, 124, 1093-1093.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Haplo+cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantationâ€”A case-cohort analysis.. Journal of Clinical Oncology, 2014, 32, 7004-7004.	1.6	4
74	Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, S162.	2.0	3
75	Bortezomib and Immune Globulin Desensitization for Donor-Specific HLA Antibodies in Haplo-Cord Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, S265.	2.0	3
76	Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplantation, 2020, 55, 2298-2307.	2.4	3
77	Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).. Blood, 2005, 106, 1856-1856.	1.4	3
78	Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma.. Blood, 2006, 108, 2953-2953.	1.4	3
79	Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50. Blood, 2014, 124, 1235-1235.	1.4	3
80	A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas. Blood, 2020, 136, 7-8.	1.4	3
81	Colonization with Vancomycin-Resistant Enterococci and Subsequent Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.9	2
82	Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cellsâ€”a singleâ€”institution experience. Transfusion, 2018, 58, 339-344.	1.6	2
83	Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2020, 61, 3024-3026.	1.3	2
84	Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. Transplantation and Cellular Therapy, 2021, 27, 499.e1-499.e6.	1.2	2
85	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. Blood, 2011, 118, 1750-1750.	1.4	2
86	Predictors and GVL Effects of UCB Chimerism after Haplo-Cord Transplant. Blood, 2015, 126, 4385-4385.	1.4	2
87	Adenovirus viremia after <i>inÂvivo</i> T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. Leukemia and Lymphoma, 2022, 63, 435-442.	1.3	2
88	Studies of White Cell, Platelet, and Coagulation Activation with Plerixafor Administration in Patients with Sickle Cell Disease. Blood, 2017, 130, 963-963.	1.4	2
89	Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities. Blood, 2021, 138, 1777-1777.	1.4	2
90	The predictive value of in-vitro techniques in acute non-lymphocytic leukemia. Leukemia Research, 1987, 11, 687-691.	0.8	1



#	ARTICLE	IF	CITATIONS
91	Enlarged Spleen Prior to Allogeneic Transplantation for Myelofibrosis Is Associated with Poor Engraftment and Increased Non-Relapse Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S285.	2.0	1
92	Colonization With Extended-Spectrum $\beta$ -Lactamase-Producing Enterobacteriaceae and Subsequent Risk of Bacteremia in Neutropenic Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.9	1
93	Seven Years of Haplo-Cord Transplantation: Immune Reconstitution and Outcomes Using Anti-Thymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S309.	2.0	1
94	Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1629-1638.	1.3	1
95	Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?. <i>Blood</i> , 2018, 132, 2172-2172.	1.4	1
96	Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2007, 110, 3024-3024.	1.4	1
97	A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory leukemia.. <i>Blood</i> , 2010, 116, 1334-1334.	1.4	1
98	A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil <sup>®</sup> ) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide. <i>Blood</i> , 2010, 116, 2258-2258.	1.4	1
99	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Blood</i> , 2011, 118, 2042-2042.	1.4	1
100	Washing Stem Cells Cryopreserved in Dimethyl Sulfoxide (DMSO) before Infusion Prevents DMSO-Related Side Effects with Little Loss of CD34 Positive Cells and Prompt Engraftment.. <i>Blood</i> , 2004, 104, 4998-4998.	1.4	1
101	Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities. <i>Blood</i> , 2010, 116, 3561-3561.	1.4	1
102	Abstract CT413: Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumors. <i>Cancer Research</i> , 2014, 74, CT413-CT413.	0.9	1
103	Stem cell transplantation for myelodysplastic syndromes: The lure of a cure. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 3-8.	2.3	0
104	Impact of Levofloxacin Prophylaxis on Rates of Bloodstream Infection and Fever and Neutropenia in Autologous Stem Cell Transplant Recipients with Lymphoma. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
105	Bendamustine and stem-cell mobilization: not so bad!. <i>Leukemia and Lymphoma</i> , 2016, 57, 993-994.	1.3	0
106	Comparison of Subcutaneous Versus Intravenous Alemtuzumab for Graft-Versus-Host Disease Prophylaxis with Fludarabine/Melphalan Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S478.	2.0	0
107	Coronavirus Infection in Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2017, 4, S730-S731.	0.9	0
108	1581. Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin. <i>Open Forum Infectious Diseases</i> , 2018, 5, S494-S494.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Hematopoietic Recovery after in-Vivo T-Cell Depleted Allogeneic Stem Cell Transplant-Effects of Major ABO Incompatibility, CMV Viremia and Acute Gvhd. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S337.	2.0	0
110	Kidney Dysfunction Post-Allogeneic Transplant: High Incidence of TMA and Kidney GvHD. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S209-S210.	2.0	0
111	Phase I Trial of CG53135-05 to Prevent Mucositis in Patients Undergoing High-Dose Chemotherapy (HDCT) and Autologous Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2004, 104, 1161-1161.	1.4	0
112	HHV-6 Reactivation after Autologous Stem Cell Transplantation Is Associated with Prolonged Hospitalization but Not with Delayed Engraftment.. <i>Blood</i> , 2004, 104, 3168-3168.	1.4	0
113	Epidemiology of Adult Acute Lymphoblastic Leukemia in Manitoba, Canada: Does This Approximate Clinical Trial Data?.. <i>Blood</i> , 2005, 106, 4554-4554.	1.4	0
114	The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 4349-4349.	1.4	0
115	Bone Marrow Engraftment Analysis. , 2011, , 147-157.		0
116	A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia. <i>Blood</i> , 2011, 118, 3030-3030.	1.4	0
117	Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population. <i>Blood</i> , 2012, 120, 4269-4269.	1.4	0
118	Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America. <i>Blood</i> , 2012, 120, 813-813.	1.4	0
119	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. <i>Blood</i> , 2013, 122, 768-768.	1.4	0
120	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. <i>Blood</i> , 2013, 122, 2145-2145.	1.4	0
121	Time until Transfusion Independence in Haplo-Cord Transplant Is Comparable to Matched Unrelated Stem Cell Transplant, a Single Institution Experience. <i>Blood</i> , 2015, 126, 4331-4331.	1.4	0
122	Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3496-3496.	1.4	0
123	Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1640-1640.	1.4	0
124	CCR5 delta32 Cord & Haploidentical Grafts: Allogeneic Stem Cell Transplant for HIV+ /AML Patient: A Case Report from the Impaact P1107 Observational Study. <i>Blood</i> , 2018, 132, 2184-2184.	1.4	0
125	A Case Report of the Benefit of Cannabidiol (Cannabidiol (CBD)-Predominant Medical Cannabis) Tj ETQq1 1 0.784314 rgBT /Overlock 5687-5687.	1.4	0
126	532. COVID-19 Pneumonia in Patients with Hematologic Malignancies â€œ A Report from the US Epicenter. <i>Open Forum Infectious Diseases</i> , 2020, 7, S333-S333.	0.9	0



#	ARTICLE	IF	CITATIONS
127	Clinical Characteristics and Risk Factors for Adverse Outcomes of Influenza Infections in Hematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2020, 136, 22-22.	1.4	0
128	Remission induction therapy of untreated acute myeloid leukemia using a nonâ€cytarabineâ€containing regimen of idarubicin, etoposide, and carboplatin. <i>Cancer</i> , 1998, 83, 1344-1354.	4.1	0